Patents Assigned to Ambit Biosciences Corporation
  • Methods of treating proliferative diseases
    Patent number: 8865710
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: October 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James
  • Methods of treatment using combination therapy
    Patent number: 8836218
    Abstract: Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: September 16, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert C. Armstrong, Barbara A. Belli
  • IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
    Publication number: 20140243525
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Application
    Filed: September 20, 2013
    Publication date: August 28, 2014
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
  • Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
    Patent number: 8703943
    Abstract: Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: April 22, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Mark W. Holladay, Eduardo Setti
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140045868
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 13, 2014
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, SHRIPAD S. BHAGWAT, BRIAN T. CAMPBELL, QI CHAO, RAFFAELLA FARAONI, MARK W. HOLLADAY, ANDILIY G. LAI, MARTIN W. ROWBOTTOM, EDUARDO SETTI, KELLY G. SPRANKLE
  • Hydrobromide salts of a pyrazolylaminoquinazoline
    Patent number: 8633209
    Abstract: Provided herein are hydrobromide salts of a pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: January 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Timothy David Gross, Patrick B. O'Donnell
  • Quinazoline compounds and methods of use thereof
    Patent number: 8633207
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: January 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Mark W. Holladay, Martin Rowbottom
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 8618289
    Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: December 31, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130317045
    Abstract: Provided herein are thienopyridine and thienopyrimidine compounds of formula (I) for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 28, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Mark W. Holladay, Eduardo Setti
  • Azolyl Urea Compounds and Methods of Use Thereof
    Publication number: 20130310357
    Abstract: Provided herein are azolyl urea compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: May 26, 2011
    Publication date: November 21, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventor: Gang Liu
  • AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130303533
    Abstract: Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 14, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Qi Chao, Michael J. Hadd, Mark W. Holladay, Martin Rowbottom
  • QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS
    Publication number: 20130296363
    Abstract: Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 7, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Raffaella Faraoni, Michael J. Hadd, Mark W. Holladay, Martin W. Rowbottom, Eduardo Setti
  • Imidazolothiazole compounds for the treatment of disease
    Patent number: 8557810
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: October 15, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
  • Imidazolothiazole compounds and methods of use thereof
    Patent number: 8551963
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: October 8, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Julius L. Apuy, Darren E. Insko, Joyce J. James
  • 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20130225578
    Abstract: Provided herein are 7-cyclylquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Mark W. Holladay, Martin W. Rowbottom
  • 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20130225615
    Abstract: Provided herein are 2-cycloquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventor: Michael J. Hadd
  • 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20130225614
    Abstract: Provided herein are 4-azolylaminoquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Applicant: Ambit Biosciences Corporation
    Inventor: Michael J. Hadd
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130096113
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicant: Ambit Biosciences Corporation
    Inventor: Ambit Biosciences Corporation
  • BIARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130035326
    Abstract: Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 7, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Mark W. Holladay, Gang Liu, Shimin Xu
  • Methods of treatment using combination therapy
    Patent number: 8357690
    Abstract: Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: January 22, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert C. Armstrong, Barbara A. Belli